Compare SGC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | LCTX |
|---|---|---|
| Founded | 1920 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.8M | 251.4M |
| IPO Year | 1994 | 1996 |
| Metric | SGC | LCTX |
|---|---|---|
| Price | $12.62 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $18.00 | $5.50 |
| AVG Volume (30 Days) | 19.1K | ★ 1.4M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $566,184,000.00 | $14,556,000.00 |
| Revenue This Year | $3.02 | $4.38 |
| Revenue Next Year | $3.83 | $10.80 |
| P/E Ratio | $90.43 | ★ N/A |
| Revenue Growth | 0.09 | ★ 53.24 |
| 52 Week Low | $8.30 | $0.88 |
| 52 Week High | $14.59 | $2.09 |
| Indicator | SGC | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 53.82 |
| Support Level | $11.72 | $0.89 |
| Resistance Level | $12.83 | $1.05 |
| Average True Range (ATR) | 0.39 | 0.06 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 20.17 | 76.44 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.